The global Gaucher disease drugs market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing cases of lysosomal storage related disorders.
Gaucher disease (GD) drugs are types of medications adopted for the treatment of an autosomal recessive metabolic disorder, a type of lysosomal storage disorder. Mutation in GBA gene can result to accumulation of glucocerebroside and reduction in development of glucocerebrosidase causes genetic conditions. The accumulation of this extra lipid in bone marrow, liver, lungs, brain, spleen, and kidney aid to form certain disorders and affects the normal functioning of a body. As per a global health report, the chance of the disease is around 1 in 100,000 people worldwide.
Low production of glucocerebrosidase breaks fatty chemical present in the body called as glucocerebroside. Gaucher cells are also called as macrophages, which are embodied with full of unprocessed glucocerebroside. These unprocessed cells, in many cases, cause serious organ dysfunction and inflammation in the body. Some of the common symptoms of the disease are blood disorders, constant fatigue, low blood platelet count, skeletal abnormalities, bruising of skin, abdominal complaints, anemia, and enlarged spleen and liver. Deficiency of the enzyme called glucocerebrosidase is a major cause of the disease. This deficiency is hereditary, which indicates that the newborn baby or child is at more risk as compare to adult.
Rising demand for the development of advanced treatment solutions are key aspects for the production of treatment drugs at affordable costs. Rising investments in development and research of activities of rare diseases are anticipated to aid the market growth.
Market Trends, Drivers, Restraints, and Opportunities
- Rising prevalence of GD worldwide is one of the major factors responsible for the market growth over the forecast period.
- Increasing clinical trials and rising development of drugs are projected to fuel the expansion of the market in the coming years.
- Convenient dosage, reduced cost, and improved efficacy in neuronopathic complications are projected to boost the market expansion during the forecast period.
- Favorable government initiatives and collaborations between various biopharmaceutical and research centers are expected to propel the market growth.
- Rising efforts of identification of more GD patients and high unmet needs are anticipated to drive the growth of the market.
- Rising cost of the treatment and lack of drugs for patients facing the last stage of the disease are key factors responsible for propelling the market growth during the forecast period.
Scope of the Report
The report on the global Gaucher disease drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Gaucher Disease Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Types (Type I, Type II, and Type III) and Therapies (Enzyme Replacement Therapy and Substrate Replacement Therapy) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Sanofi Genzyme, Shire, Pfizer, and Johnson & Johnson |
Market Segment Insights
Type I segment is projected to hold a major market share
On the basis of types, the Gaucher disease drugs market is segmented into type I, type II, and type III. The type I segment is expected to hold a key share of the market during the forecast period due to rising adoption of the drug type for the disease treatment. This disorder is normally developed between the age of childhood and adulthood; condition of type I disease does not hamper the central nervous system (CNS), making it non-neuronopathic in nature.
However, the type II and type III are relatively rare types of disease. Both these types are neuronopathic, which cause complications in the central nervous system. New-born with type II GD have low rate of survival due to severity and treatment of disease progression.
Enzyme replacement therapy segment to account for a key market share
Based on therapies, the market is bifurcated into enzyme replacement therapy and substrate replacement therapy. The enzyme replacement therapy (ERT) segment is expected to account for a key share of the market during the forecast period due to strong commercial performances of Cerezyme, Vpriv, and Elelyso. Moreover, rising adoption of ERT for the treatment of GD and increasing awareness about usage of ERT among the patients are projected to propel the segment growth. ERT is generally used for the treatment of type I and type III. However, the substrate replacement therapy (SRT) segment is anticipated to expand at a rapid pace during the forecast period due to rising inclination toward SRT type.
North America is expected to dominate the market
In terms of regions, the Gaucher disease drugs market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period owing to easy accessibility to the treatment, increasing awareness about treatment among people, and rising number of GD patients. However, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years. Japan is projected to show a fastest growth rate owing to rising awareness about disease among people, high unmet clinical requirements, and increasing disposable income.
Segments
Segments Covered in the Report
The global Gaucher disease drugs market has been segmented on the basis of
Types
Therapies
- Enzyme Replacement Therapy
- Substrate Replacement Therapy
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Sanofi Genzyme
- Shire
- Pfizer
- Johnson & Johnson
Competitive Landscape
Key players competing in the Gaucher disease drugs market include Sanofi Genzyme, Shire, Pfizer, and Johnson & Johnson. Major market players adopt several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.
Request For Customization
Enquiry Before Buying
Speak With Analyst
